News

New medications coming soon: Here’s what’s been FDA approved in 2025 so far
GoodRx reports that in 2025, novel drug and biosimilar approvals lag slightly behind last year, while first generic approvals ...
FDA Names Biotech Veteran George Tidmarsh To Lead Drug Evaluation Division
George Tidmarsh appointed to lead FDA drug review division amid staffing cuts and scrutiny over accelerated approvals and ...
STAT4d
New head of FDA drug center is a biotech veteran and an outspoken critic of the academic establishment
“Dr. Tidmarsh is an accomplished physician-scientist and leader whose experience spans the full arc of drug development — ...
PharmExec3d
FDA Appoints George Tidmarsh as Director of Center for Drug Evaluation and Research
Biotech veteran and Stanford physician-scientist brings 30 years of translational research and regulatory experience to ...
BioPharma Dive3d
Former biotech executive appointed to lead FDA drug office
George Tidmarsh, a Stanford University physician who founded Horizon Pharma and later ran La Jolla Pharma, was named head of ...
FDA names former pharmaceutical company executive to oversee US drug program
The Food and Drug Administration on Monday named a longtime pharmaceutical executive to run the agency’s drug program, the ...
FDA Picks George Tidmarsh to Head Center for Drug Evaluation and Research
By Stephanie Brown HealthDay ReporterWEDNESDAY, July 23, 2025 (HealthDay News) -- The U.S. Food and Drug Administration has appointed George Francis Tidmarsh, M.D., Ph.D., as director of the Center ...
FDA appoints biotech executive as top drug regulator under RFK Jr.
Food and Drug Administration commissioner Marty Makary has chosen former biotech executive George Tidmarsh as the agency’s ...
The Pharma Letter4d
FDA appoints biotech veteran to lead drug evaluation center
The US regulator has tapped Stanford University physician-scientist and former biotech executive George Tidmarsh to serve as ...
Boise State Public Radio1d
Doctors urge FDA to remove black box warning on hormone therapy for menopause
The FDA may remove the warning labels on hormone replacement therapies used to treat the symptoms of menopause. Doctors say ...
US FDA eliminates risk evaluation, mitigation strategies for CAR-T cancer therapies
The U.S. Food and Drug Administration said on Friday it had eliminated risk evaluation and mitigation strategies (REMS), a ...
FDA appoints biotech veteran George Tidmarsh to lead drug evaluation division
Stanford's George Tidmarsh has authored 143 scientific papers and patents, as well as played a central role in developing ...